Ca2+ oscillations in response to methamphetamine in dopamine neurons of the ventral tegmental area in rats subchronically treated with this drug.
Mesolimbic dopamine neurons in the ventral tegmental area (VTA), which project to the nucleus accumbens and prefrontal cortex, play an important role in the regulation of emotion, rewarding, and cognition. The dopamine neurons in the VTA have also been implicated in schizophrenia and drug abuse. Methamphetamine (METH) can induce a schizophrenia-like psychosis. Thus, the VTA is a likely effector site for the action of METH. However, effects of METH on the mesolimbic dopamine neurons are largely unknown. We treated adult SD rats with METH (5 mg/kg/day) or saline for 7 days, isolated single VTA neurons from these treated rats, and monitored the neuronal activities by measuring cytosolic Ca2+ concentration ([Ca2+]i), which was followed by immunocytochemical identification of dopamine neurons. Acute administration of METH under superfusion conditions concentration-dependently increased [Ca2+]i in VTA dopamine neurons isolated from METH- and saline-treated rats. Furthermore, acutely administered METH induced oscillations of [Ca2+]i only in the dopamine neurons of the METH-treated group. The METH-induced [Ca2+]i oscillations were inhibited by Ca2+-free conditions and by Ca2+ channel blockers. In conclusion, subchronic METH treatment sensitizes VTA dopamine neurons to this drug, resulting in induction of [Ca2+]i oscillations. This sensitization of VTA dopamine neurons may account, at least in part, for the psycho-stimulant effects of METH, such as the dependence on and sensitization to METH.
Uramura
K
K
Department of Neuropsychiatry, Faculty of Medicine, Kagoshima University, Japan.
Yada
T
T
Muroya
S
S
Takigawa
M
M
D000818:Animals; D002118:Calcium / Q000378:metabolism; D002121:Calcium Channel Blockers / Q000494:pharmacology; D020013:Calcium Signaling / Q000187:drug effects*; D000697:Central Nervous System Stimulants / Q000008:administration & dosage*; D002614:Chelating Agents / Q000494:pharmacology; D004298:Dopamine / Q000378:metabolism*; D004305:Dose-Response Relationship, Drug; D004533:Egtazic Acid / Q000494:pharmacology; D007279:Injections, Subcutaneous / Q000379:methods; D008297:Male; D008694:Methamphetamine / Q000008:administration & dosage*; D009433:Neural Inhibition / Q000187:drug effects; D009474:Neurons / Q000187:drug effects* / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D017557:Ventral Tegmental Area / Q000166:cytology*; D020960:omega-Conotoxins / Q000494:pharmacology
D002121:Calcium Channel Blockers; D000697:Central Nervous System Stimulants; D002614:Chelating Agents; D020960:omega-Conotoxins; D008694:Methamphetamine; D004533:Egtazic Acid; D002118:Calcium; D004298:Dopamine